(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus ...

Eliquis is prescribed to treat or prevent blood clots and to reduce the risk of stroke in certain adults. Its dosage varies based on the condition being treated and other factors. The standard Eliquis ...

Apixaban oral tablet is available as a brand-name drug. It doesn’t have a generic version. Brand name: Eliquis. Apixaban only comes as a tablet you take by mouth. Apixaban is used to treat and prevent ...

Please provide your email address to receive an email when new articles are posted on . Label-concordant dosing may benefit patients on dialysis with nonvalvular atrial fibrillation more than ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), regardless of dosage, was associated with significantly less major bleeding compared with warfarin in a particularly high-risk ...

ROCHESTER, MN — Inappropriate dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for atrial fibrillation (AF) was common in a large US cohort study, including inappropriate dosage ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...